Pipeline of New Drug Treatment for Non-alcoholic Fatty Liver Disease/Metabolic Dysfunction-associated Steatotic Liver Disease.

34 In another phase 2 trial of patients with MASH, aldafermin (an engineered FGF19 analog) reduced liver fat and showed a trend toward fibrosis improvement. 68 FGF21 is another member of the FGF family that preserves insulin-sensitizing and antifibrotic properties without mitogenic effects. 35 It has improved steatosis, insulin resistance, and liver stiffness in short-term trials and is actively under clinical investigation as a treatment for MASH.

also in 53,322 other papers